627 - Results of adjuvant chemotherapy after hepatic and/or lung metastases resection of colorectal cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer Agents
Colon and Rectal Cancer
Biological Therapy
Presenter Eddy Isabel Gutierrez
Authors E.I. Gutierrez1, A. Sancho Gutiérrez1, M. Arruti2, S. Carrera3, I. Rubio2, I. Marrodan2, A. Muñoz2, E. Azkona2, A. Buque2, G. Lopez-Vivanco2
  • 1Hospital of Cruces, 48903 - Barakaldo/ES
  • 2Medical Oncology, Hospital of Cruces, 48903 - Barakaldo/ES
  • 3Oncology, Hospital de Cruces, 48903 - BARAKALDO , Vizcaya/ES



Adjuvant chemotherapy following metastases resection of colorectal cancer is recommended although the benefit has not been clearly demonstrated in clinical trials.


We have performed a retrospective review of patients (pt) with hepatic and lung metastases treated with surgery and adjuvant chemotherapy in our institution, from January-96 to December-11.


One hundred ninety one patients were identified. Patient characteristics: median age 62 years (23-81). Sex: 114 male (60%) 77 female (40%). Primary tumour location: colon 129 (67.5%) rectal 62 (32.5%). Metastases location: hepatic 143 (75%), lung 46 (24%) lung and hepatic 2 (1%). Primary tumour stage: I stage 2 (1%) II stage 50 (26%) III stage 87 (46%) IV stage 52 (27%). Adjuvant chemotherapy: 5-Fluorouracil + Leucovorin 70 (36.6%), Irinotecan-based 9 (4.7%) Oxaliplatin-based 112 (58.6%). Presurgical CEA: normal 146 pt (76%) increased 45 (24%). Number of metastases: one 87 pt (45%), two 65 (34%), three 18 pt (9%), more than three 21 pt (11%). Treatment compliance: 149 pt (78%) completed planned treatment; 42 pt (22%) did not complete it due to toxicity or progressive disease. Recurrence was diagnosed in 105 pt (55%). Surgery for relapsed disease was performed in 105 pt (38%). Median overall survival has not been reached, as only 77 pt have died. Estimated 5-years survival is 62%. Median progression free survival is 30 months. Significant factors for survival: sex (better female), node positive primary tumour, increased CEA, and more than 3 metastases. There were no differences between chemotherapy schedules.


Surgery of hepatic and lung metastases from colorectal cancer has a curative goal. Adjuvant chemotherapy could achieve an improvement of survival by decreasing recurrence rate. We must emphasize that patients included in this analysis have good prognostic factors so results should be interpreted with caution.


All authors have declared no conflicts of interest.